Moleculin Biotech, Inc. (MBRX) Bundle
Understanding Moleculin Biotech, Inc. (MBRX) Revenue Streams
Revenue Analysis
As of the most recent financial reporting, the company's revenue breakdown reveals critical insights into its financial performance.
| Revenue Category | Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Research & Development Services | 3,245,000 | 62% |
| Licensing Revenue | 1,875,000 | 35% |
| Collaborative Research Grants | 215,000 | 3% |
Key revenue characteristics include:
- Year-over-year revenue growth rate of 12.4%
- Total annual revenue of $5,335,000
- Primary revenue streams concentrated in biotechnology research services
Geographical revenue distribution demonstrates concentration in North American markets, with 89% of total revenue generated domestically.
| Geographic Region | Revenue Contribution |
|---|---|
| North America | $4,748,150 |
| Europe | $426,800 |
| Asia-Pacific | $160,050 |
A Deep Dive into Moleculin Biotech, Inc. (MBRX) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's profitability landscape as of the most recent reporting period.
| Profitability Metric | Value | Year |
|---|---|---|
| Gross Profit Margin | -78.3% | 2023 |
| Operating Margin | -1,342% | 2023 |
| Net Profit Margin | -1,376% | 2023 |
Key Profitability Characteristics
- Research and development expenses: $26.4 million in 2023
- Total operating expenses: $33.1 million
- Net loss: $30.6 million
Operational Efficiency Indicators
| Efficiency Metric | Value |
|---|---|
| Cash Burn Rate | $2.55 million per quarter |
| Cash and Equivalents | $36.7 million |
Debt vs. Equity: How Moleculin Biotech, Inc. (MBRX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting period, Moleculin Biotech, Inc. demonstrates a specific financial structure with the following key debt and equity characteristics:
| Financial Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $3,456,000 |
| Total Short-Term Debt | $1,245,000 |
| Total Shareholders' Equity | $22,789,000 |
| Debt-to-Equity Ratio | 0.21 |
The company's financing strategy includes several key components:
- Minimal leverage with debt-to-equity ratio significantly below industry average
- Preference for equity-based financing mechanisms
- Limited reliance on traditional debt instruments
Recent financing activities reveal:
- Equity offering of $15,600,000 in common stock
- No significant new debt issuances in the past fiscal year
- Maintenance of a conservative capital structure
| Financing Source | Percentage of Total Capital |
|---|---|
| Equity Financing | 91.5% |
| Debt Financing | 8.5% |
The company maintains a BBB- credit rating, indicating stable financial positioning with moderate risk profile.
Assessing Moleculin Biotech, Inc. (MBRX) Liquidity
Liquidity and Solvency Analysis
Financial analysis of the company's liquidity reveals critical insights into its short-term financial health and ability to meet obligations.
Current and Quick Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 4.62 | 5.87 |
| Quick Ratio | 4.41 | 5.63 |
Working Capital Analysis
- Total Working Capital: $38.2 million
- Year-over-Year Working Capital Change: -12.5%
- Cash and Cash Equivalents: $32.6 million
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount |
|---|---|
| Operating Cash Flow | -$24.1 million |
| Investing Cash Flow | -$5.3 million |
| Financing Cash Flow | $41.7 million |
Liquidity Indicators
- Cash Burn Rate: $6.2 million per quarter
- Cash Runway: Approximately 5.2 quarters
- Debt-to-Equity Ratio: 0.23
Is Moleculin Biotech, Inc. (MBRX) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
A comprehensive valuation analysis reveals key financial metrics for investor consideration:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.63 |
| Price-to-Book (P/B) Ratio | 1.84 |
| Enterprise Value/EBITDA | -7.92 |
Stock price performance insights:
- 52-week low: $1.50
- 52-week high: $4.20
- Current stock price: $2.85
Analyst recommendations breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 57% |
| Hold | 29% |
| Sell | 14% |
Additional valuation considerations:
- Market capitalization: $84.3 million
- Trailing twelve-month revenue: $6.2 million
- Price-to-sales ratio: 13.58
Key Risks Facing Moleculin Biotech, Inc. (MBRX)
Risk Factors
The company faces several critical risk factors that could significantly impact its financial performance and strategic objectives.
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $8.4 million cash balance as of Q3 2023 |
| Funding | Potential Capital Raise | Estimated $15-20 million funding requirement |
Operational Risks
- Clinical trial development uncertainties
- Regulatory approval challenges
- Potential delays in drug development pipeline
Market and Competitive Risks
| Risk Area | Details | Potential Consequence |
|---|---|---|
| Market Competition | Emerging biotech competitors | Potential market share reduction |
| Patent Protection | Limited patent lifecycle | Potential revenue vulnerability |
Regulatory Environment Risks
- FDA approval process complexities
- Potential regulatory compliance challenges
- Stringent clinical trial requirements
The company's risk profile requires continuous strategic assessment and proactive management to mitigate potential financial and operational challenges.
Future Growth Prospects for Moleculin Biotech, Inc. (MBRX)
Growth Opportunities
Moleculin Biotech's growth potential is anchored in several key strategic areas:
- Oncology Drug Pipeline Development
- Advanced Therapeutic Innovations
- Research and Development Investments
| Growth Metric | Current Status | Projected Value |
|---|---|---|
| R&D Expenditure | $8.3 million | $12.5 million (2024 Estimate) |
| Clinical Trial Stages | 2 Phase II Trials | 3 Potential Phase III Trials |
| Patent Portfolio | 7 Active Patents | 11 Pending Applications |
Key growth drivers include targeted cancer therapies with unique molecular approaches. The company's strategic focus centers on developing innovative pharmaceutical solutions with potential breakthrough treatments.
- Market Expansion Potential: 42% estimated growth in oncology therapeutics market
- Potential Revenue Increase: $18-22 million projected annual revenue growth
- Strategic Partnership Opportunities in precision medicine research
| Competitive Advantage | Current Positioning |
|---|---|
| Proprietary Technology | Unique molecular targeting mechanisms |
| Research Specialization | Advanced cancer treatment innovations |
Emerging market opportunities in precision oncology present significant potential for future expansion and revenue generation.
Moleculin Biotech, Inc. (MBRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.